An Australian stem cell and regenerative medicine company

November 16, 2023

Proactive Investors interview

Following the completion of the site initiation visit at Weill Cornell Medical Center in New York for the Phase 2 clinical trial of CYP-001 in High-Risk acute Graft versus Host Disease (HR-aGvHD), Dr Kilian Kelly spoke with Proactive Investors about this important milestone. 

Watch the interview here